Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana

AIDS Research and Human Retroviruses

Volumn 34, Issue 8, 2018, Pages 667-671

  Diphoko, Thabo ^a,b   Gaseitsiwe, Simani ^a,c   Kasvosve, Ishmael ^b   Moyo, Sikhulile ^a,c   Okatch, Harriet ^d   Musonda, Rosemary ^a,c   Wainberg, Mark ^e   Makhema, Joseph ^a,c   Marlink, Richard ^f   Novitsky, Vladimir ^a,c   Essex, Max ^a,c  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b UNIVERSITY OF BOTSWANA   (Botswana)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Drug resistance; Efavirenz; Etravirine; Nevirapine; rilpivirine

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; POL PROTEIN; PYRIDAZINE DERIVATIVE;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; MALE; PRIORITY JOURNAL; STRUCTURAL GENE; BOTSWANA; DRUG EFFECT; GENETICS; GENOTYPING TECHNIQUE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIAL SENSITIVITY TEST; MUTATION; PREVALENCE; PROCEDURES; TREATMENT FAILURE; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; BOTSWANA; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; NEVIRAPINE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; PYRIDAZINES; RILPIVIRINE; TREATMENT FAILURE; YOUNG ADULT;

EID: 85051078738     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2017.0135     Document Type: Article

References (31)

1. Riddler SA, Haubrich R, DiRienzo AG, et al.: Classsparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
2. Ministry of Health Botswana: Botswana National HIVand AIDS National Treatment Guidelines Ministry of Health, Gaborone, 2012.
3. Anta L, Llibre JM, Poveda E, et al.: Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 2013;27:81-85.
4. FDA notifications. Rilpivirine approved for HIV treatment. AIDS Alert 2011;26:82-84.
5. FDA approves new HIV drug after priority review. U.S. Food and Drug Administration. AIDS Patient Care STDs 2008;22:159-161.
6. Das K, Jain B, Patel HS: Nile blue in Triton-X 100/benzenehexane reverse micelles: A fluorescence spectroscopic study. Spectrochim Acta A Mol Biomol Spectrosc 2004;60: 2059-2064.
7. Xu HT, Colby-Germinario SP, Huang W, et al.: Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other non-nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2013;57: 5649-5657.
8. Das K, Bauman JD, Clark AD, Jr, et al.: High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A 2008;105:1466-1471.
9. Asahchop EL, Wainberg MA, Oliveira M, et al.: Distinct resistance patterns to etravirine and rilpivirine in viruses containing non-nucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 2013;27:879-887.
10. Wensing AM, Calvez V, Gunthard HF, et al.: Update of the drug resistance mutations in HIV-1. Top Antivir Med 2017; 2017:132-133.
11. Molina JM, Cahn P, Grinsztejn B, et al.: Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatmentnaive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-246.
12. Cohen CJ, Andrade-Villanueva J, Clotet B, et al.: Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-237.
13. UNAIDS: UNAIDS Report on the Global AIDS Epidemic j 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland, 2010.
14. Gaolathe T, Wirth KE, Holme MP, et al.: Botswanas progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: A population-based survey. Lancet HIV 2016;3:e221-e230.
15. Thior I, Lockman S, Smeaton LM, et al.: Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-Tochild HIV transmission in Botswana: A randomized trial: The Mashi Study. JAMA 2006;296:794-805.
16. Wester CW, Thomas AM, Bussmann H, et al.: Nonnucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-Treated adults in Botswana. AIDS 2010;24(Suppl 1):S27-S36.
17. Bussmann H, Wester CW, Thomas A, et al.: Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: Two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr 2009;51:37-46.
18. Shapiro RL, Thior I, Gilbert PB, et al.: Maternal singledose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-To-child HIV transmission in Botswana. AIDS 2006;20:1281-1288.
19. Doualla-Bell F, Gaseitsiwe S, Ndungu T, et al.: Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother 2004;15:189-200.
20. Anta L, Blanco JL, Llibre JM, et al.: Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. J Antimicrob Chemother 2013;68:1994-2002.
21. Pineda-Pena AC, Faria NR, Imbrechts S, et al.: Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol 2013;19:337-348.
22. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S: MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013;30:2725-2729.
23. Stanford University. HIV Drug Resistance Database. Available at http://hivdb.stanford.edu/cgi-bin/MutPrevBySubtype Rx.cgi, accessed March 24, 2018.
24. Sluis-Cremer N, Jordan MR, Huber K, et al.E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings. Antiviral Res 2014;107:31-34.
25. Osmanov S, PattouC, WalkerN, Schwardlander B, Esparza J: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002;29:184-190.
26. Gatanaga H, Murakoshi H, Hachiya A, et al.: Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity. Clin Infect Dis 2013;57:1051-1055.
27. Rambaut A, Posada D, Crandall KA, Holmes EC: The causes and consequences of HIV evolution. Nat Rev Genet 2004;5:52-61.
28. Carlson JM, Le AQ, Shahid A, Brumme ZL: HIV-1 adaptation to HLA: A window into virus-host immune interactions. Trends Microbiol 2015;23:212-224.
29. Novitsky V, Wester CW, DeGruttola V, et al.: The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses 2007;23:868-878.
30. Jagodzinski LL, Cooley JD, Weber M, Michael NL: Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol 2003;41:998-1003.
31. Mouafo LC, Pere H, Ndjoyi-Mbiguino A, et al.: LETTER to the EDITOR performance of the ViroSeq(R) HIV-1 genotyping system v2.0 in central Africa. Open AIDS J 2015;9:9-13.